Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Broccoli Sprout Dose Response

This study has been completed.
Sponsor:
Collaborators:
Qidong Liver Cancer Institute
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier:
NCT02656420
First received: January 5, 2016
Last updated: May 23, 2016
Last verified: May 2016
  Purpose
This study will examine the extent to which lower doses of a broccoli-derived beverage enhance the detoxication of air pollutants excreted in urine as compared to an maximal dose shown to be effective previously.

Condition Intervention Phase
Environmental Carcinogenesis
Drug: Broccoli Sprout Powder
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Prevention
Official Title: Broccoli Sprout Dose Response

Further study details as provided by Johns Hopkins Bloomberg School of Public Health:

Primary Outcome Measures:
  • Sulforaphane Bioavailability Measured in Sequential 12-Hour Urine Samples [ Time Frame: 2 weeks ]
    Urinary excretion of broccoli-derived sulforaphane metabolites: sulforaphane-mercapturic acid. The metabolite will be measured in the sequential 12-hour urine collections from each participant over the 2-week period.


Secondary Outcome Measures:
  • Modulation of Air Pollutant Excretion in Sequential 12-Hour Urine Samples [ Time Frame: 2 weeks ]
    Benzene-mercapturic acid excretion will be measured in the sequential 12-hour urine samples collected across the 2-week study period.


Enrollment: 170
Study Start Date: January 2016
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
Drug: Broccoli Sprout Powder
Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebo.
Experimental: High Dose Broccoli Sprout
Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
Drug: Broccoli Sprout Powder
Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebo.
Experimental: Medium Dose Broccoli Sprout
Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
Drug: Broccoli Sprout Powder
Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebo.
Experimental: Low Dose Broccoli Sprout
Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
Drug: Broccoli Sprout Powder
Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebo.

Detailed Description:
This is a 2-week placebo control Phase II broccoli sprout intervention to be conducted in Qidong, P.R. China. Up to twelve hundred people from the farming townships will be screened and one hundred seventy eligible individuals will be enrolled in the study. Participants will be randomized into 4 treatment groups: one will receive a juice beverage containing a standard dose of glucoraphanin- and sulforaphane-rich broccoli sprout powder mixed in pineapple juice, lime juice and water, the second will receive one-half dose, the third one-fifth dose and the fourth group will receive placebo beverage containing pineapple juice, lime juice and water. Participants will drink their assigned beverage every evening and provide consecutive 12-hour urine collections throughout the duration of the study.
  Eligibility

Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • in good general health with no history of chronic illness
  • normal liver function tests
  • normal renal function tests

Exclusion Criteria:

  • personal history of cancer except for non-melanoma skin cancer
  • use of prescribed medicines
  • for women, a positive pregnancy test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02656420

Locations
China, Jiangsu
Qidong Liver Cancer Institute
Qidong, Jiangsu, China, 226200
Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
Qidong Liver Cancer Institute
National Cancer Institute (NCI)
Investigators
Principal Investigator: Thomas Kensler, PhD Johns Hopkins Bloomberg School of Public Health
  More Information

Publications:
Responsible Party: Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier: NCT02656420     History of Changes
Other Study ID Numbers: IRB00006734
R01CA190610 ( US NIH Grant/Contract Award Number )
Study First Received: January 5, 2016
Last Updated: May 23, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Carcinogenesis
Neoplastic Processes
Neoplasms
Pathologic Processes

ClinicalTrials.gov processed this record on April 24, 2017